CFM
RLAY icon

Catalyst Funds Management’s Relay Therapeutics RLAY Stock Holding History

Catalyst Funds Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,500
Closed -$39.8K – 627
2025
Q2 		$39.8K Buy
11,500
+1,400
+14% +$4.16K 0.01% 387
2025
Q1 		$26.5K Buy
+10,100
New +$39.6K 0.01% 434
2024
Q3 		– Sell
-2,500
Closed -$16.3K – 1562
2024
Q2 		$16.3K Buy
+2,500
New +$17.1K ﹤0.01% 750

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Catalyst Funds Management's RLAY Position: Q3 2025 in Review

Catalyst Funds Management sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 11,500 shares — an estimated $39.8K sold.

Catalyst Funds Management first reported a position in RLAY in Q2 2024 and held it in 3 quarters. The position peaked at $39.8K in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • Catalyst Funds Management reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 11,500 Relay Therapeutics shares in Q3 2025, an estimated $39.8K.
  • Catalyst Funds Management first reported a position in Relay Therapeutics in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Relay Therapeutics position peaked at $39.8K in Q2 2025.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.